Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

96.850
+6.2006.84%
Volume:26.71M
Turnover:2.54B
Market Cap:165.90B
PE:-1.51K
High:98.450
Open:91.900
Low:89.700
Close:90.650
52wk High:106.000
52wk Low:28.650
Shares:1.71B
HK Float Shares:1.71B
Volume Ratio:1.08
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:3.44%
PB:10.45
PE(LYR):-1,512.95
PS:13.19

Loading ...

INNOVENT BIO (01801) Grants a Total of 20,800 Share Options

Stock News
·
Aug 29

Innovent Biologics Inc. Announces New Share Options and Restricted Shares Plan as Part of 2024 Share Scheme

Reuters
·
Aug 29

Northbound Capital Activity | Northbound Funds Net Purchase HK$12.046 Billion, BABA-W Accumulates Ahead of Earnings Release, XIAOMI-W Faces Continued Selling Pressure

Stock News
·
Aug 29

CICC: Maintains Outperform Rating on INNOVENT BIO (01801), Raises Target Price to HK$118.3

Stock News
·
Aug 29

Stability Ahead? Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 2.5%, INNOVENT BIO Leads with 6% Gain, Institutions: Innovative Drugs Remain Core Bull Market Track

Deep News
·
Aug 29

Nomura Adjusts Innovent Biologics' Price Target to HK$105.08 From HK$89.80, Keeps at Buy

MT Newswires Live
·
Aug 28

INNOVENT BIO (01801) Target Price Raised to HK$120 as Interim Results Beat Expectations, "Buy" Rating Maintained

Stock News
·
Aug 28

Hong Kong Stock Morning Brief | MIIT Supports Direct Satellite Phone Applications, MEITUAN-W (03690) H1 Revenue Up 14.7% YoY

Stock News
·
Aug 28

Innovent Biologics CFO: Expect Mazdutide Approval for Diabetes Indication in a Couple of Months

THOMSON REUTERS
·
Aug 27

Innovent Biologics CFO : for 2026 Mazdutide for Diabetes Will Play in Self-Pay Market

THOMSON REUTERS
·
Aug 27

Innovent Biologics Turns to H1 Profit

MT Newswires Live
·
Aug 27

Innovent Biologics CFO - Mazdutide Initial Sales Trend Very in Line With Internal Expectation

THOMSON REUTERS
·
Aug 27

Press Release: Innovent Announces 2025 Interim Results and Business Updates

Dow Jones
·
Aug 27

INNOVENT BIO (01801) Reports Interim Results with Profit of RMB 834 Million, Turning from Loss to Profit Year-over-Year

Stock News
·
Aug 27

BRIEF-Innovent Biologics Logs H1 Adjusted Net Income RMB 1,213.2 Mln

Reuters
·
Aug 27

Innovent Biologics H1 Net Income RMB 834.3 Million

THOMSON REUTERS
·
Aug 27

INNOVENT BIO (01801): Stephen A. Sherwin Appointed as Independent Non-Executive Director

Stock News
·
Aug 26

Hong Kong Stock Movement | Innovative Drug Concept Stocks See Expanding Declines as Trump Announces Swift Pharmaceutical Tariffs, Morgan Stanley Expects Low Likelihood of BD Taxation

Stock News
·
Aug 26

Innovent Biologics Announces U.S. FDA Ind Approval for the First Global Mrct Phase 3 Study (Marslight-11) of Ibi363 (Pd-1/Il-2Α-Bias) in Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 25

INNOVENT BIO's Yu Dechao: Chinese Innovative Drugs Face Three Major Hurdles in Global Expansion

Deep News
·
Aug 17